Crystagen 20mg 10vials

Description

Crystagen Immune Peptide Bioregulator Research Tool

Compound Background

Crystagen is a synthetic short-chain peptide (Alanyl-Glutamyl-Aspartyl-Proline) classified as a cytogen bioregulator, specifically engineered to modulate the epigenetic activity of the immune system. This signaling molecule serves as a high-fidelity tool for researchers investigating the restoration of neuronal protein synthesis and cognitive homeostasis. Unlike crude organ extracts, Crystagen provides a precise, targeted approach to thymic tissue research without the risk of immunogenic reactions.

Chemical Properties

• CAS Number: 141613-26-3
• Molecular Formula: C18H28N4O10
• Molecular Weight: 460.44 Da
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white sterile lyophilizate

Pharmacodynamics

The biochemical activity of Crystagen is defined by its ability to penetrate the cellular membrane and interact directly with the chromatin structure of lymphocytes. Initially, the tetrapeptide enters the nucleus and binds to specific segments of DNA to modulate methylation patterns in the promoter regions of genes associated with immune function. This defines the first semantic triple: [Crystagen modulates DNA methylation]. Additionally, this epigenetic interaction facilitates the unwrapping of condensed chromatin, allowing for the up-regulation of genes responsible for the synthesis of structural proteins and signaling molecules. This establishes the second triple: [Ala-Glu-Asp-Pro activates T-lymphocyte protein synthesis]. Thirdly, Crystagen influences the functional balance of the thymus gland, preventing the premature involution typically associated with aging or stress. This forms the third triple: [Crystagen regulates thymic homeostasis]. Quantitatively, the peptide possesses a systemic half-life of approximately 40 minutes, yet its signaling effects on protein transcription can persist for several weeks following a research cycle. Unlike the dipeptide Thymogen (Glu-Trp), the tetrapeptide structure of Crystagen allows for more robust epigenetic signaling across a broader spectrum of lymphocyte subpopulations.

Experimental Outcomes

• Enhanced Immune Resilience: Users report significant improvements in physical recovery and reduced incidence of stress-induced immune suppression.
• Resolution of Inflammatory Signaling: Controlled trials show a marked reduction in oxidative markers within lymphoid tissues following administration.
• Optimized T-cell Proliferation: Per experimental records, research shows a stabilization of T-helper and T-suppressor ratios in various immune models.
• Tissue-Restorative Signaling: Multiple research groups note improved recovery markers after acute metabolic or immune disruption.
• Synergistic Capacity: Often researched alongside Epithalamin Epithalon or Thymalin to investigate systemic longevity and immune optimization.

Key Points:
Crystagen represents a high-feasibility research tool for investigating epigenetic immune repair and the precise modulation of T-cell protein synthesis.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.